Core Viewpoint - Elicio Therapeutics has initiated an underwritten public offering of its common stock and accompanying warrants to support its development pipeline and general corporate purposes [7]. Company Overview - Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for aggressive cancers, utilizing AMP technology to enhance immune responses [9]. - The company's R&D pipeline includes therapeutic cancer vaccines targeting mKRAS-driven cancers (ELI-002) and BRAF-driven cancers and p53 hotspot mutations (ELI-007 and ELI-008) [9]. Offering Details - The public offering includes common stock, pre-funded warrants, and accompanying common warrants, with all securities being offered by Elicio [7]. - A shelf registration statement for these securities was filed with the SEC and became effective on June 11, 2024 [8]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the terms of the offering [7][8]. Use of Proceeds - The net proceeds from the offering will be used for advancing the development pipeline, working capital, and general corporate purposes [1].
Elicio Therapeutics Announces Proposed Public Offering